Alpha-1-antitrypsin gene therapy-inhalation - Aradigm/geneRx+

Drug Profile

Alpha-1-antitrypsin gene therapy-inhalation - Aradigm/geneRx+

Alternative Names: Alphagen

Latest Information Update: 19 Apr 2007

Price : $50

At a glance

  • Originator Aradigm Corporation; geneRx+
  • Developer Aradigm Corporation
  • Class Gene therapies
  • Mechanism of Action Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Emphysema

Most Recent Events

  • 26 Sep 2002 Preclinical trials in emphysema in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top